ATENEA-Co-300 study

Phase 1

Not yet recruiting

• Conditions: Confirmed patients to COVID-19; COVID-19; SARS-CoV2; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases

• Registration Number: RPCEC00000317
• Lead Sponsor: Center for Genetic Engineering and Biotechnology (CIGB), in Havana

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-05-28
• Study Completion: 2020-07-17
• Results First Posted: 2020-07-31
• Last Update Posted: 2024-08-19

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1) Patients who meet the diagnostic criteria for COVID 19 in categories 1 through 4 of the NIH guidelines.
2) Age over 18 years.
3) Voluntariness of the patient by signing the informed consent.

Exclusion Criteria

1) Pregnancy or lactation at the time of inclusion in the study.
2) Patients included in another clinical trial.
3) Diseases that compromise the patient's state of consciousness or their possibility of giving their informed consent or collaborating in the trial.
4) Critical illness, category 5 of the NIH Guidelines.

Study & Design

• Study Type: Interventional
• Study Design: Not specified